Chronic Immune Activation Underlies Morbid Obesity: Is IDO A Key Player?
The DOI matches its Crossref record.
Abstract
Morbid obesity is associated with low-grade systemic inflammation and immune activation. Thereby various pro-inflammatory cytokines like TNF-alpha, IL-1, IL-6, IFN-gamma and hormones, such as leptin are synthesized and released in human adipose tissue. The immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) is widely distributed in mammals and is inducible preferentially by IFN-gamma. IDO degrades the essential amino acid tryptophan to form N-formyl kynurenine which, depending on cell type and enzymatic repertoires, is subsequently converted to finally form niacin. More recently, it has been proposed that activation of IDO is also critically involved in the regulation of immune responses. In obesity plasma tryptophan concentrations have been shown to be decreased and to be independent of weight reduction or dietary intake. In addition, we previously demonstrated that IDO mediated tryptophan catabolism due to chronic immune activation is the cause for such reduced tryptophan plasma levels in morbidly obese patients compared to lean individuals. Furthermore, these tryptophan metabolic changes may subsequently reduce serotonin production and cause mood disturbances, depression, and impaired satiety ultimately leading to increased caloric uptake and obesity. IDO-mediated tryptophan degradation due to chronic immune activation can therefore be considered as the driving force for food intake. We here review the potential pathogenic links between chronic immune activation and decreased IDO mediated tryptophan and serotonin levels in morbid obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
How important is tryptophan in human health?
Kałużna-Czaplińska, J., Gątarek, P., Chirumbolo, S., Chartrand, M. S., & Bjørklund, G. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1357534 · Cited by 333
“…or prevention of changes in the ratio of the intake/bioavailable Trp and other signals related to obesity that activates the immune system and inflammation, in obese patients with bariatric surgical intervention a reduction in this ratio or of immune markers was not found (Brandacher et al., 2007).”
BackgroundInfluentialInflammation and Oxidative Stress in an Obese State and the Protective Effects of Gallic Acid
Dludla, P. V., Nkambule, B. B., Jack, B., Mkandla, Z., Mutize, T., Silvestri, S., Orlando, P., Tiano, L., Louw, J., & Mazibuko-Mbeje, S. E. (2018) · Nutrients · doi:10.3390/nu11010023 · Cited by 286
Oxenkrug, G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8497-4 · Cited by 254
André, C., Dinel, A.-L., Ferreira, G., Layé, S., & Castanon, N. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.03.012 · Cited by 241
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
Role of Adiposity-Driven Inflammation in Depressive Morbidity
Capuron, L., Lasselin, J., & Castanon, N. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.123 · Cited by 182
“In addition, severely obese individuals have been found to display lower circulating tryptophan levels together with greater kynurenine levels in comparison to lean controls, consistent with inflammationdriven activation of IDO pathway (Brandacher et al, 2007).”
BackgroundSen, Z. D., Danyeli, L. V., Woelfer, M., Lamers, F., Wagner, G., Sobanski, T., & Walter, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.020 · Cited by 65
Navrotskaya, V., Oxenkrug, G., Vorobyova, L., & Summergrad, P. (2015) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000120 · Cited by 14
Role of metabolic dysfunction in treatment resistance of major depressive disorder
Toups, M. S., & Trivedi, M. H. (2011) · Neuropsychiatry · doi:10.2217/npy.11.49 · Cited by 9
Metadata
- Authors
- Brandacher, G., Hoeller, E., Fuchs, D., & Weiss, H.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-04-01
- Volume
- 8
- Issue
- 3
- Pages
- 289-295
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2101823049
- Cited by
- 111
- References
- 0
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.